Last updated:
March 09, 2012
 Documents identified with this icon are in Portable Document Format (PDF)
and require the
Adobe
Acrobat Reader
Perinatal Data are integrated with Perinatal
Conference Data in the
Perinatal Data Page.
Abacavir Reactive
HLA-B*5701 Restricted Memory CD8+ T Cells Are Present in
Abacavir-unexposed Donors
A Lucas, M Lucas, R Pavlos,
et al
PDF Poster
Abstract
PDF POSTER
CVD Risk Markers in Patients Receiving Abacavir, Tenofovir, and Zidovudine: The
Nucleoside Inflammation, Coagulation,
and Endothelial Function (NICE) Study
PDF Poster
Abstract
PDF POSTER
Renal Function Declines More in Tenofovir- than
Abacavir-based ART in Low-body-weight Treatment-naïve Patients with HIV
Infection
T Nishijima, H Gatanaga, H
Komatsu, et al
PDF Poster
Abstract
Molecular
Basis for the Immunostimulatory Activity of Abacavir via TLR-8
I MacLeod, C Rowley, M
Essex
6th IAS Conference on HIV Pathogenesis,
Treatment
and Prevention |
- POSTER
Prospective epidemiological study of the prevalence of human leukocyte antigen
(HLA)-B*5701 in Chilean HIV-1-infected subjects
P. Ferrer, M. Durán, R. Tordecilla, D. Carvajal, J. Galaz
Poster
Abstract
- POSTER
Detection of abacavir hypersensitivity by ELISpot method
S. Esser, R. Jablonka, F.M. Heinemann, et al
Poster
Abstract
-
Antiretroviral drugs
and risk of cardiovascular disease: a systematic review and meta-analysis
J. Bavinger, M. Desai, I. Olkin, et al
Abstract
-
Risk of
antiretroviral-associated renal toxicity in HIV-infected patients with altered
basal renal function
P. Safont Gasó, P. WIkman, M. del Palacio ,M.J. Pérez-Elías, et al
Abstract
-
In vivo effects of HAART
on platelet activating factor (PAF) metabolism and levels in HIV-infected
patients:
a potential mechanism of
abacavir-related cardiovascular risk
M. Chini, A.B. Tsoupras, N. Mangafas, et al
Abstract
-
Progression to impaired
estimated glomerular filtration rate (eGFR) between antiretroviral therapy
regimens in the Canadian Observational Cohort (CANOC) collaboration
S.R. Hosein, K. Johns, K. Chan, et al
Abstract
-
A WEEK-IN-REVIEW FEATURED
REPORT
POSTER
Changes in Cardiovascular Biomarkers with Abacavir: a
Randomized, 96-Week Trial
A Humphries J Amin. D
Cooper, et al
17th CROI
PDF Poster
Abstract
-
POSTER
Abacavir Induces Human Leukocyte Endothelial Cell Interactions
C de Pablo, S Orden, J
Peris, et al
PDF Poster
Abstract
-
POSTER
Abacavir, a Competitive Inhibitor of Soluble Guanylyl Cyclase, Increases
Platelet
Reactivity
P Baum, G Kosikova, S
Galkina, et al
PDF Poster
Abstract
|
-
A WEEK-IN-REVIEW FEATURED
REPORT
POSTER
Changes in Cardiovascular Biomarkers with Abacavir: a
Randomized, 96-Week Trial
A Humphries J Amin. D
Cooper, et al
17th CROI
PDF Poster
Abstract
-
POSTER
Abacavir Induces Human Leukocyte Endothelial Cell Interactions
C de Pablo, S Orden, J
Peris, et al
PDF Poster
Abstract
-
POSTER
Abacavir, a Competitive Inhibitor of Soluble Guanylyl Cyclase, Increases
Platelet
Reactivity
P Baum, G Kosikova, S
Galkina, et al
PDF Poster
Abstract
|
5th IAS Conference on HIV Pathogenesis,
Treatment
and Prevention |
|
- POSTER
Successful management of suspected abacavir hypersensitivity reactions among
African children in the ARROW (AntiRetroviral Research fOr Watoto) trial
P. Nahirya-Ntege, B. Naidoo, K.J. Nathoo
PDF Poster
Abstract
-
Abacavir treatment
and biomarkers associated with cardiovascular disease
(CVD) in
HIV-1-infected patients on effective antiretroviral therapy
A. De Luca, K. De Gaetano Donati, A. Cozzi-Lepri, et al
Abstract
-
Changes in
biomarkers of cardiovascular risk after a switch to abacavir in HIV-1 infected
individuals
receiving combination antiretroviral therapy
U.S. Kristoffersen, K. Kofoed, G. Kronborg, et al
-
Abstract
-
Abacavir use and
risk of acute myocardial infarction and cerebrovascular disease in the
HAART era
R. Bedimo, A. Westfall, H. Drechsler P. Tebas
Abstract
-
No evidence for
recent abacavir/lamivudine use in promoting inflammation, endothelial
dysfunction,
hypercoagulability, or insulin resistance in virologically suppressed
HIV-infected
patients: a substudy of the BICOMBO randomized clinical trial (ISRCTN6189
E. Martinez, M. Larrousse, I. Perez, et al
Abstract
|
-
Abacavir and
Cardiovascular Risk
P Reiss
Abstract
-
POSTER
Prevalence and in
vitro Characteristics of Reverse Transcriptase N348I Mutation in Non-B
Subtypes, in the
Absence of Viral Load Monitoring: The Development of ART in Africa, Nevirapine
or Abacavir Substudy
A McCormick, A Burke, P
Katundu, et al
PDF Poster
Abstract
-
Platelet
Hyper-Reactivity in HIV-1-infected Patients on Abacavir-containing ART
C Satchell, E O'Connor, A Peace, et al
Abstract
-
Inflammatory
Markers among Abacavir and non-Abacavir Recipients in the Womens’ Interagency
HIV Study
and the Multicenter AIDS Cohort Study
F Palella, S Gange, R Elion, et al
Abstract
-
Abacavir Use
Is Not Associated with Lack of Virologic Response in ARV-treated
HIV/HCV-co-infected Patients
Receiving Pegylated Interferon and Ribavirin
V Amorosa, J Slim, K Mounzer,
et al
Abstract
-
Association of
Abacavir and HIV Disease Factors with Endothelial Function in Patients on
Long-term Suppressive
ART
P Hsue, Y Wu, A Schnell,et al
Abstract
-
Viral Dynamics
and Pharmacokinetics in vivo of Tenofovir Disoproxil Fumarate and
Abacavir: Evidence of a
Non-additive Antiviral Effect
M Goicoechea, S Jain, C Kemper, et al
Abstract
-
The
Convenience of Flow Cytometry for HLA-B*5701 Screening to Prevent Abacavir
Hypersensitivity Reactions
P Airò, M Scarsi, A Malagoli, et al
Abstract
Ninth International Congress on Drug Therapy in HIV Infection
|
-
Relation
between adverse effects of ARV treatment and underlying risk in number needed to
treat to harm (NNTH)
– myocardial infarction and abacavir use
JD Kowalska, O Kirk, A Mocroft,et al
PDF Abstract
-
A cross-sectional
comparison of renal function in patients on stable abacavir (ABC) or tenofovir
(TDF) containing therapy
Waters LJ, Randell P, Jackson AGA, et al
Abstract
-
A cross-sectional
comparison of serum bone markers in patients on stable abacavir (ABC) or
tenofovir (TDF)
containing therapy
Waters LJ, Randell P, Jackson AGA, et al
Abstract
-
Cost-effectiveness analysis of HLA-B*5701 screening in preventing abacavir
hypersensitivity in Spain
Nieves D, de la Calle O, Iribarren JA, Rivero A, et al
Abstract
-
CNA110329: a prospective
epidemiological study to determine the prevalence of HLA-B*5701 in HIV-1
infected
individuals in five European countries
Prins JM, Rauch A, Bergin C, et al
Abstract
-
FREE trial:
induction therapy with ART (abacavir/lamivudine/lopinavir/r) followed by
maintenance regimen
with triple NRTI, compared to continued ART
Sprenger HG, ten Napel CHH, Vriesendorp R, et al
Abstract
-
Changes in hematological
parameters after switching treatment of HIV-infected patients from zidovudine to
abacavir or tenofovir DF
Viergever RF, Berg MJ, van Solinge WW, et al
Abstract
-
Kidney tubular
abnormalities in HIV patients treated with tenofovir with normal glomerular
function –
results of a prospective study on 284 patients
Labarga P, Barreiro P, Martin-Carbonero L, et al
Abstract
-
Is abacavir (ABC)-containing combination antiretroviral therapy (CART)
associated with myocardial
infarction (MI)? No association identified in pooled summary of 54 clinical
trials
A.
Cutrell, J. Hernandez, J. Yeo,
et al
Abstract
-
Prospective HLA-B*5701 screening for abacavir hypersensitivity
saves costs
E. Wol , M. Stoll , M. Becker-Andre, J. Bogner
Abstract
-
Cost-effectiveness of HLA*B-5701 testing prior to initiation of
abacavir sulfate
R. Farkouh, S. Earnshaw , T. Kauf , et al
Abstract
-
Adverse drug events in HIV: patch test and
hypersensitivity reaction to abacavir (HSR-ABC)
S. Giorgini , C. Martinelli , A. Carocci , et al
Abstract
-
A
meta-analysis of simplified maintenance therapy with abacavir-based triple
nucleoside regimens
M.
Cruciani, S. Parisi, G. Serpelloni
Abstract
-
HLA-B*5701 screening reduces abacavir hypersensitivity reactions (ABC HSR);
multiple lines of evidence
to establish a new standard of care
P.
Wannamaker, S. Mallal, E. Phillips, et al
Abstract
Do
Thymidine Analogues, Abacavir, Didanosine and Lamivudine Contribute to the
Risk of Myocardial
Infarction? The D:A:D Study
C Sabin, S Worm, R Weber, et al
Abstract
A WEEK IN REVIEW FEATURED REPORT
Outcomes of Abacavir- and Efavirenz-based HAART: Comparison of ACTG 5095 Trial
Results
with
Observational Cohort Studies
M Mugavero, M May, H Ribaudo, et al
Abstract
POSTER
Changes in Body Composition Attributable to
Lamivudine, Stavudine, Zidovudine, and Abacavir
in HIV-infected Persons Initiating ART
J Shlay, S Sharma, G Bartsch, et al
PDF Poster
Abstract
Pharmacological Mechanisms Leading to Early Virologic Failure of 2
Antiretroviral Regimens:
Didanosine, Lamivudine, and Tenofovir, and Abacavir, Lamivudine, and Tenofovir
LBi, J Russel, N Mordwinkin, et al
Abstract
Genetic
Factors Predicting Abacavir Hypersensitivity and Tolerance in HLA-B*5701+
Individuals:
Combined Analysis from PREDICT-1, SHAPE, and a Multinational Study
D Nolan, D Thorborn, M Schaefer,
et al
Abstract
Genetic
Testing in HIV Care: Clinical Effect and Cost-effectiveness of HLA-B*5701
Screening to
Guide First-line Abacavir Use
B Schackman, C Scott, R Walensky, et al
Abstract
HCP5-Single Nucleotide
Polymorphism: A Simple Screening Tool for Predicting Abacavir
Hypersensitivity Reactions
S Colombo, A Rauch, M Rotger,
et al
Abstract
Selection of K65R Mutation in HIV-2 Patients Exposed to Abacavir
B Rodes, C Toro, R Colombatti, et al
Abstract
|
